Search for Clinical Trial Results

Sponsored By

Carcinoma, Neuroendocrine - 23 Studies Found

Status Study
Not yet recruiting Study Name: Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients
Condition: Neuroendocrine Carcinomas
Date: 2015-05-04
Interventions: Drug: TLC 388 40 mg/m2 of TLC 388, given as a 30 (+3) minute intravenous infusion, on Days 1, 8 and 15 o
Completed Study Name: Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)
Condition: Neuroendocrine Carcinoma
Date: 2014-07-24
Interventions: Drug: Everolimus , temozolomide
Not yet recruiting Study Name: Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma
Condition: Pulmonary Large Cell Neuroendocrine Carcinoma
Date: 2016-10-22
Interventions:
  • Drug: etoposide plus carboplatin

Completed Study Name: Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma
Condition: Neuroendocrine Carcinoma
Date: 2008-01-22
Interventions:
  • Drug: Avastin 15 mg/kg By Vein
Not yet recruiting Study Name: Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer
Condition: Neuroendocrine Carcinomas
Date: 2016-06-29
Interventions:
  • Drug: Folfiri-bevacizumab
  • Drug: Folfiri
Completed Study Name: A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas
Condition: Gastrointestinal Neuroendocrine Carcinomas
Date: 2014-08-07
Interventions:
  • Drug: NAB paclitaxel 100 mg/m2
Completed Study Name: Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract
Condition:
  • Gastrointestinal Cancer
  • Carcinoma, Neuroendocrine

Date: 2006-07-13
Interventions:
  • Drug: Cisplatin Cisplatin 25 m
Completed Study Name: Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma
Condition: Neuroendocrine Carcinoma
Date: 2008-04-18
Interventions: Drug: Atiprimod Oral, 14 days on / 14 days off; 30mg capsules
Completed Study Name: Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
Condition: Neuroendocrine Carcinoma
Date: 2006-10-11
Interventions: Drug: Atiprimod oral, 14 days on / 14 days off; 30mg capsules
Completed Study Name: Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma
Condition: Neuroendocrine Carcinoma
Date: 2005-09-12
Interventions:
  • Drug: Paclitaxel
  • Drug: Carboplatin
Next >>>